Paper of the Month - May, 2010

0 rating

Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Blackwell KL, Burstein HJ, Storniolo AM et al.


READER POLL

Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE